Why the study?
Can immunohistochemical markers differentiate lymphangiosarcoma from angiosarcoma?
Can immunohistochemical markers differentiate lymphangiosarcoma from angiosarcoma?
Recent characterization of biologic markers allows greater differentiation between lymphangiosarcoma and angiosarcoma, potentially providing new therapeutic targets.
Answers are grounded in this paper and cite their sources.
May aid rare sarcoma subtyping; leaves open prospective validation before clinical adoption.
BACKGROUND: Lymphangiosarcoma is a rare, aggressive malignancy that originates from the endothelial cells lining lymphatic vessels and carries an extremely poor prognosis. Its clinical and histologic features are often indistinguishable from angiosarcoma. OBJECTIVE: We sought to better characterize the clinical and histologic features of lymphangiosarcoma. METHODS: Case report and review of the literature. RESULTS: A number of immunohistochemical markers, including Von Willebrand factor, Ulex europaeus agglutinin 1, CD31, VEGFR-3, D2-40, Prox-1, can be used to help differentiate lymphatic from vascular tissue. CONCLUSIONS: Recent characterization of several new biologic markers has allowed greater differentiation between these tumors and may provide new therapeutic targets for treatment.
No takes yet. Share an insight, caveat, or question.
Mamelak et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: